» Articles » PMID: 17312126

IL-21 is Produced by NKT Cells and Modulates NKT Cell Activation and Cytokine Production

Overview
Journal J Immunol
Date 2007 Feb 22
PMID 17312126
Citations 171
Authors
Affiliations
Soon will be listed here.
Abstract

The common gamma-chain cytokine, IL-21, is produced by CD4(+) T cells and mediates potent effects on a variety of immune cells including NK, T, and B cells. NKT cells express the receptor for IL-21; however, the effect of this cytokine on NKT cell function has not been studied. We show that IL-21 on its own enhances survival of NKT cells in vitro, and IL-21 increases the proliferation of NKT cells in combination with IL-2 or IL-15, and particularly with the CD1d-restricted glycosphingolipid Ag alpha-galactosylceramide. Similar to its effects on NK cells, IL-21 enhances NKT cell granular morphology, including granzyme B expression, and some inhibitory NK receptors, including Ly49C/I and CD94. IL-21 also enhanced NKT cell cytokine production in response to anti-CD3/CD28 in vitro. Furthermore, NKT cells may be subject to autocrine IL-21-mediated stimulation because they are potent producers of this cytokine following in vitro stimulation via CD3 and CD28, particularly in conjunction with IL-12 or following in vivo stimulation with alpha-galactosylceramide. Indeed, NKT cells produced much higher levels of IL-21 than conventional CD4 T cells in this assay. This study demonstrates that NKT cells are potentially a major source of IL-21, and that IL-21 may be an important factor in NKT cell-mediated immune regulation, both in its effects on NK, T, and B cells, as well as direct effects on NKT cells themselves. The influence of IL-21 in NKT cell-dependent models of tumor rejection, microbial clearance, autoimmunity, and allergy should be the subject of future investigations.

Citing Articles

Pro- and anti-inflammatory cytokines: the hidden keys to autoimmune gastritis therapy.

Cascetta G, Colombo G, Eremita G, Garcia J, Lenti M, Di Sabatino A Front Pharmacol. 2024; 15:1450558.

PMID: 39193325 PMC: 11347309. DOI: 10.3389/fphar.2024.1450558.


High Interleukin 21 Levels in Patients with Systemic Lupus Erythematosus: Association with Clinical Variables and rs2221903 Polymorphism.

Espinoza-Garcia N, Salazar-Camarena D, Marin-Rosales M, Reyes-Mata M, Ramirez-Duenas M, Munoz-Valle J J Clin Med. 2024; 13(15).

PMID: 39124778 PMC: 11313274. DOI: 10.3390/jcm13154512.


invariant Natural Killer T cell therapy as a novel therapeutic approach in hematological malignancies.

Boonchalermvichian C, Yan H, Gupta B, Rubin A, Baker J, Negrin R Front Transplant. 2024; 3:1353803.

PMID: 38993780 PMC: 11235242. DOI: 10.3389/frtra.2024.1353803.


HLA-DR Expression in Natural Killer Cells Marks Distinct Functional States, Depending on Cell Differentiation Stage.

Kust S, Ustiuzhanina M, Streltsova M, Shelyakin P, Kryukov M, Lutsenko G Int J Mol Sci. 2024; 25(9).

PMID: 38731828 PMC: 11083986. DOI: 10.3390/ijms25094609.


Therapeutic potential of interleukin-21 in cancer.

Isvoranu G, Chiritoiu-Butnaru M Front Immunol. 2024; 15:1369743.

PMID: 38638431 PMC: 11024325. DOI: 10.3389/fimmu.2024.1369743.